EE79 A Cost of Control Analysis of Once-Weekly Subcutaneous Semaglutide Versus Dulaglutide for Bringing Patients to Treatment Targets in China

In the SUSTAIN 7 randomized controlled trial, once-weekly subcutaneous semaglutide (OW) (s.c.) 0.5mg was associated with greater reduction in glycated hemoglobin (HbA1c) and body weight people type 2 diabetes mellitus (T2DM) comparing dulaglutide 1.5mg. The present study estimated annual cost per patient achieving HbA1c treatment targets loss responses OW s.c. Chinese healthcare system setting over a one-year period. proportions of patients single composite endpoints related to glycemic control, weight, hypoglycemia outcomes were taken from 7. included medication needle cost. Cost control calculated as each medication, expressed 2020 RMB (CNY), divided by proportion endpoint. more effective at bringing showed lower costs for all modeled endpoints. triple endpoint CNY 9,598 13,395 1.5mg, representing 40% larger For an HbA1c≤6.5%，HbA1c＜7%, ≥1.0% with≥3.0% loss, loss≥5% loss≥10%, would be 32%, 28%, 92%, 86% 121% 1.5mg than 0.5mg, respectively. provides better value money T2DM China.